Clinical trials: End Stage Disease
End Stage Renal Disease, Cardiovascular Diseases
Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration
The aim of this study is to evaluate haemodialysis treatment using a medium cut-off dialysis membrane (Theranova) compared with on-line haemodiafiltration treatment with respect to markers of endothelial health (plasma…
- Conditions
- End Stage Renal Disease, Cardiovascular Diseases, Inflammation
- Trial name
- MoDal (NCT03510520)
- Testing
- Medium Cut-Off Haemodialysis, On-Line Haemodiafiltration
- Where
- United Kingdom
- Volunteers
- 63 people
- Sponsor
- Manchester University NHS Foundation Trust
End Stage Liver Disease, Lung Cancer
Antinociceptive Modalities on Ischemia Reperfusion Injury
Postoperative pain caused by surgery-associated tissue injury is a major concern for all the clinical practitioners. Because it affects multiple systems and induces physiological, immunological and psychological changes.
- Trial name
- NCT01932918
- Testing
- Patient controlled analgesia
- Where
- Taiwan
- Volunteers
- 142 people
- Sponsor
- National Taiwan University Hospital
End Stage Renal Disease
Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis
The time on peritoneal dialysis may be limited for a significant number of patients that use this modality of renal replacement therapy due to the inability of the peritoneal membrane to clear solutes or achieve adequate…
- Trial name
- NCT02133313
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Alabama at Birmingham
End Stage Renal Disease, Hemodialysis
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
Cardiovascular disease is the primary cause of death in patients with end stage renal disease (ESRD). New research suggests that the high risk of death may be partly due to high levels of fibrosis and a loss of small blood…
- Trial name
- LAST-D (NCT01855334)
- Testing
- Spironolactone, L-arginine
- Where
- 3 sites in United States
- Sponsor
- Brigham and Women's Hospital
Lipoprotein(a), Lipoprotein-apheresis
Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )
Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (>200 nmol/L) who…
- Conditions
- Lipoprotein(a), Lipoprotein-apheresis, Double-filtration Plasmapheresis, Hemodialysis Complication
- Trial name
- LiPo-A (NCT07390604)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Osteoarthritis, Knee
Cryotherapy Effectiveness in Individuals With End Stage Knee Osteoarthritis - a Case Series
The purpose of this case series will be to provide a detailed description of a standardized short-term cryotherapy application protocol using validated functional outcome measures in individuals with end stage KOA
- Trial name
- NCT03582644
- Testing
- Cryotherapy
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Universidade Federal de Sao Carlos
Chronic Myeloid Leukemia
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on…
- Trial name
- NCT01627132
- Testing
- Dasatinib
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Shimousa Hematology Study Group
End Stage Renal Disease
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
This single center, Phase I/II, exploratory study has been modified to a safety/efficacy study providing all patients with IVIG and Rituximab.
- Trial name
- NCT01178216
- Testing
- Rituxan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanley Jordan, MD
Uremic Pruritus, Chronic Kidney Disease-associated Pruritus
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
Several studies investigated the effectiveness of Gabapentin in Uremic Pruritus (UP). No previous studies investigated the use of fexofenadine in UP.
- Conditions
- Uremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis, End-stage Renal Disease
- Trial name
- NCT06466421
- Testing
- Fexofenadine, Gabapentin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Kidney Disease
Inspiratory Muscle Training in Patients With End-stage Renal Disease
Background: Patients with chronic kidney disease on hemodialysis may have reduced diffusion capacity, lung function and gas exchange due to mechanical and hemodynamic changes in the respiratory system, and decreased respiratory…
- Trial name
- NCT02599987
- Testing
- POWERbreathe® Classic Light
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- Universidade Federal de Pernambuco
End Stage Renal Disease
Effect of Behavioral Intervention on Interdialytic Weight Gain in Patients Undergoing Hemodialysis
A randomized clinical trial will be conducted in which effect of behavioral intervention (Text message of dietary salt and fluid restriction) on inter-dialytic weight gain in hemodialysis patients.
- Trial name
- NCT04892225
- Testing
- Technology-supported behavioral intervention (text message)
- Where
- Pakistan
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Farooq Hospital - West Wood Branch
End Stage Renal Disease, Renal Failure
Homocysteine Study (HOST)
The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage…
- Trial name
- NCT00032435
- Testing
- PAL-40 Active
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 2,003 people
- Sponsor
- US Department of Veterans Affairs
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
- Trial name
- PK (NCT01708889)
- Testing
- BMS-914143 (Peginterferon Lambda-1a)
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Kidney Disease, End-stage Renal Disease
Home-based Exercise in Chronic Kidney Disease
A home-based exercise program will be implemented in three different groups of participants: advanced chronic kidney disease, end-stage renal disease in substitutive treatment hemodialysis or peritoneal dialysis.
- Trial name
- HBCKD-BCN (NCT03621176)
- Testing
- Home-based exercise
- Where
- Spain
- Volunteers
- 57 people
- Sponsor
- Cardenal Herrera University
Cirrhosis, End Stage Liver DIsease
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
- Conditions
- Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
- Trial name
- NCT05205954
- Testing
- Hepatology Home Hospital
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Renal Insufficiency, Chronic
Is Hemodialysis Associated With Cardiac Markers Change?
Hemodialysis (HD) triggers recurrent and cumulative ischemic insults to the brain and the heart. Cooled dialysate may have a protective effect on major organs and improve hemodynamic tolerability of dialysis.
- Trial name
- NCT04929366
- Testing
- Hypothermic dialysis followed with routine dialysis, Routine dialysis followed with hypothermic dialysis
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Ziv Hospital
Delayed Graft Function, End Stage Renal Disease
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients.
- Conditions
- Delayed Graft Function, End Stage Renal Disease, Kidney Transplantation
- Trial name
- NCT06367205
- Testing
- Goal-Directed Fluid Therapy (GDFT), Regular Fluid Therapy
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- RenJi Hospital
End-Stage Kidney Disease
PrEscription of Intra-Dialytic Exercise to Improve quAlity of Life in Patients With Chronic Kidney Disease
The PEDAL study aims to evaluate the effectiveness of a 9-month intradialytic exercise training intervention designed to improve quality of life (QOL) and alleviate functional limitations in patients with stage 5 Chronic Kidney…
- Trial name
- PEDAL (NCT02222402)
- Testing
- INTRA-DIALYTIC EXERCISE TRAINING
- Where
- United Kingdom
- Volunteers
- 335 people
- Sponsor
- King's College Hospital NHS Trust
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
End Stage Renal Disease
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
The purpose of the TiME Trial is to determine whether dialysis facility implementation of a minimum hemodialysis session duration of 4.25 hours (versus usual care) for patients with end-stage renal disease initiating treatment…
- Trial name
- TiME (NCT02019225)
- Testing
- Dialysis session of at least 4.25 hours
- Where
- 2 sites in United States
- Volunteers
- 7,053 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.